Patient Characteristics, Outcome and Thromboembolic Events Among Adult Critically Ill COVID-19 Patients With Different Anticoagulant Regimes at One of the Biggest Emergency Hospitals in Northern Europe, Sweden
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 166
- 试验地点
- 1
- 主要终点
- 28-days ICU mortality
研究概览
简要总结
The aims of the study are to to associate anticoagulation (AC) regime with outcome in critically ill patients with Covid-19. This will be done by describe baseline characteristics and comorbidities before hospital admission, level of organ support and dose of AC treatment and associate this with 28 days survival, survival outside ICU, thromboembolic event and bleeding complications.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •laboratory confirmed positive test for SARS-CoV-2
- •admitted to ICU because of critical illness due to covid-19
排除标准
- •patients with treatment for thromboembolic complications at arrival to the ICU
- •short ICU length of stay defined as discharged the same or the following day as ICU admission
研究组 & 干预措施
thrombose prophylaxis
The dose used to prevent thromboembolic complication in critically ill
干预措施: Dose of Tinzaparin or Dalteparin (Drug)
double thrombose prophylaxis
Double the dose used to prevent thromboembolic complication in critically ill
干预措施: Dose of Tinzaparin or Dalteparin (Drug)
full dose anticoagulant
Dose used to treat thromboembolic event
干预措施: Dose of Tinzaparin or Dalteparin (Drug)
结局指标
主要结局
28-days ICU mortality
时间窗: 28 days from ICU-admission
28-days ICU mortality from admission to the ICU. Discontinue of ICU-care to palliative care counts as death.
次要结局
- Incidence of thromboembolic events(28 days from ICU-admission)
- Incidence of bleeding events(28 days from ICU-admission)
- ICU-free days alive from ICU-admission.(28 days from ICU-admission)
研究者
Christer Svensen
Professor
Karolinska Institutet